Novo Nordisk’s semaglutide product to lose patent protection in China next year, according to L.E.K. Consulting.

The Food and Drug Administration has designated Hadlima (adalimumab-bwwd) an interchangeable biosimilar to Humira (adalimumab).

Oncology biosimilars significantly reduce financial toxicity in cancer care, as highlighted in 2 abstracts presented at the ...

Biocon's share price saw an uptick following key regulatory approvals in India for its Liraglutide drug, which is used in the ...

Prescription drugs prices have rapidly increased, but opting for generic medications and incorporating lifestyle changes are some ways to cut costs.

However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

The Food and Drug Administration (FDA) has approved Starjemza ® (ustekinumab-hmny), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Starjemza, ...

From five years of sales declines to nine consecutive quarters of growth, it’s hard to deny that Teva’s revamp under CEO Richard Francis is paying off. | By 2030, Teva now expects to achieve at least ...

Biocon said that it has received an approval from the Drugs Controller General of India (DCGI), under the central drugs standard control organisation (CDSCO), for its Liraglutide drug substance.

Some Michigan hospitals are marking up prices by thousands of dollars above what they pay manufacturers for certain prescription drugs, according to a new report from the Michigan Health Purchasers ...

The HHS said it has taken the first step toward implementing most-favored-nation pricing for prescription drugs.

Lupin has signed a licence and supply agreement with SteinCares to commercialise its biosimilar ranibizumab in Latin American ...